{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:11:26Z","timestamp":1773299486284,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Botulinum toxin A is considered an effective treatment for involuntary facial movements. We examined whether treatment efficacy maintained or changed over time with two products, Botox and Dysport, in patients with hemifacial spasm, facial synkinesis and benign essential blepharospasm.<\/jats:p>\n            <jats:p>We retrospectively investigated 87 consecutive patients (51 women, 36 men) who had undergone treatment for \u22656\u200ayears. Long-term effects, as well as side effects of Botox or Dysport local injections were evaluated. The first three treatments were considered the titration period and not taken into account when testing for dose changes.<\/jats:p>\n            <jats:p>Mean treatment duration was 10\u200ayears (range 6\u201311, SD 1.0), 2441 treatments were administered, 1162 with Botox and 1279 with Dysport, the two brands were interchanged as needed. Good to full improvement was seen in 90% of patients both with both brands. Injection doses and treatment responses were consistent during the study with both drugs. No major side effects were reported, and relatively few minor adverse events were reported, with clear reduction from the titration period (6.1%), to the remainder of the study (3.9%).<\/jats:p>\n            <jats:p>Botulinum toxin (BTX-A) is a satisfactory long-term treatment without need for dose increase over. Both Botox and Dysport were effective when used interchangeably.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026481","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T13:33:43Z","timestamp":1624455223000},"page":"e26481","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-6054","authenticated-orcid":false,"given":"Samih","family":"Badarny","sequence":"first","affiliation":[{"name":"Department of Neurology, Galilee Medical Center Naharyia"},{"name":"Bar Ilan Faculty of Medicine, Safed"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphiq","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Edmond J. Safra Brain Research Center & Department of Learning Disabilities, University of Haifa, Haifa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zvi","family":"Susel","sequence":"additional","affiliation":[{"name":"Neurology Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Zaina","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Zvulun Medical Clinic, Kiryat Bialik"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rema","family":"Nasar","sequence":"additional","affiliation":[{"name":"Bnai Zion Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazid","family":"Badarny","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Rambam Medical Center, Haifa, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov Disord"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0036-1571952","article-title":"Botulinum toxin treatment of blepharospasm, orofacial\/oromandibular dystonia and hemifacial spasm","volume":"36","author":"Karp","year":"2016","journal-title":"Sem Neurol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/lary.22404","article-title":"Botulinum toxin in the treatment of facial synkinesis and hyperkinesis","volume":"122","author":"Filipo","year":"2012","journal-title":"Laryngoscope"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V","article-title":"Hemifacial spasm: clinical findings and treatment","volume":"21","author":"Wang","year":"1998","journal-title":"Muscle Nerve"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.joto.2015.06.002","article-title":"Advances in microvascular decompression for hemifacial spasm","volume":"10","author":"Cui","year":"2015","journal-title":"J Otol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3171\/2015.1.JNS142714","article-title":"Failed microvascular decompression surgery for hemifacial spasm due to persistent neurovascular compression: an analysis of reoperations","volume":"124","author":"Bigder","year":"2016","journal-title":"J Neurosurg"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1288\/00005537-197911000-00020","article-title":"Mechanisms of synkinesis","volume":"89","author":"Crumley","year":"1979","journal-title":"Laryngoscope"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1212\/WNL.44.11.2165","article-title":"Aberrant reinnervation of facial musculature in a subhuman primate: a correlative analysis of eyelid kinematics, muscle synkinesis, and motoneuron localization","volume":"44","author":"Baker","year":"1994","journal-title":"Neurology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp.64.6.751","article-title":"Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases","volume":"64","author":"Jitpimolmard","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R10-20250504","first-page":"837","article-title":"Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin","volume":"139","author":"Kraft","year":"1988","journal-title":"CMAJ"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0161-6420(95)30757-9","article-title":"Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm","volume":"102","author":"Ainsworth","year":"1995","journal-title":"Ophthalmology"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.59.3.418","article-title":"Botulinum toxin A treatment for primary hemifacial spasm. A 10-year multicenter study","volume":"59","author":"Defazio","year":"2002","journal-title":"Arch Neurol"},{"key":"R13-20250504","first-page":"363","article-title":"Long-term treatment of blepharospasm with botulinum toxin type A","volume":"4","author":"Nussgens","year":"1995","journal-title":"Ger J Ophthalmol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.imbio.2011.08.009","article-title":"Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT\/B molecule","volume":"217","author":"Atassi","year":"2012","journal-title":"Immunobiology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jneuroim.2016.09.013","article-title":"Submolecular recognition regions of the H(N) domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients","volume":"300","author":"Oshima","year":"2016","journal-title":"J Neuroimmunol"},{"key":"R16-20250504","first-page":"520","article-title":"Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox","volume":"10","author":"Badarny","year":"2008","journal-title":"IMAJ"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","article-title":"Dose standardization of botulinum toxin","volume":"59","author":"Marion","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/ceo.12165","article-title":"Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm","volume":"42","author":"Ababneh","year":"2014","journal-title":"Clin Experiment Ophthalmol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4103\/0028-3886.236959","article-title":"Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm","volume":"66","author":"Pandey","year":"2018","journal-title":"Neurology India"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.4103\/0028-3886.226441","article-title":"Botulinum toxin in movement disorders","volume":"66","author":"Tater","year":"2018","journal-title":"Neurology India"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14737175.2017.1262258","article-title":"Immunological aspects of botulinum toxin therapy","volume":"17","author":"Dressler","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1002\/mds.20022","article-title":"Clinical presentation and management of antibody-induced failure with botulinum toxin therapy","volume":"19","author":"Dressler","year":"2004","journal-title":"Mov Disord"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay","volume":"23","author":"Brin","year":"2008","journal-title":"Mov Disord"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","article-title":"Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes","volume":"24","author":"Cillino","year":"2010","journal-title":"Eye"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","article-title":"Long-term botulinum toxin efficacy, safety, and immunogenicity","volume":"20","author":"Mejia","year":"2005","journal-title":"Mov Disord"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2013.02.001","article-title":"Long term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome","volume":"156","author":"Czyz","year":"2013","journal-title":"Am J Ophtalmol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079905X36396","article-title":"Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm","volume":"21","author":"Binari","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10072-011-0672-7","article-title":"Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story","volume":"33","author":"Bentivoglio","year":"2012","journal-title":"Neurol Sci"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.toxicon.2011.04.019","article-title":"Flu-like symptoms following botulinum toxin therapy","volume":"58","author":"Baizabal-Carvallo","year":"2011","journal-title":"Toxicon"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12640-013-9400-9","article-title":"Flu-like symptoms and associated immunological response following therapy with botulinum toxins","volume":"24","author":"Baizabal-Carvallo","year":"2013","journal-title":"Neurotox Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:05:13Z","timestamp":1746338713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":34,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026481","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"2020-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}